AbbVie offers the ImmunoGen FR-ASSIST™ FOLR1 Immunohistochemistry (IHC) Sponsored Testing Program as a way to increase access to testing for patients with epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). The program also assists healthcare providers with making informed treatment decisions for these patients. Under an arrangement with ImmunoGen, FOLR1 IHC testing is available at no cost for patients with EOC that meet certain eligibility requirements.
– While AbbVie provides financial support for this program, tests and services are performed by diagnostic labs. Healthcare professionals must confirm that patients meet certain criteria to use the program. – AbbVie receives de-identified aggregate data from this program, but at no time does the sponsor receive patient-identifiable information. The sponsor may use healthcare professional contact information for research and commercial purposes. – Healthcare professionals or patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any sponsor product. – No patients, healthcare professionals, or payers, including government payers, are billed for this program.
This program offers a genetic testing initiative generously supported by GSK, AstraZeneca, Merck, and Genentech. This program provides no-cost genetic testing on a first-come, first-served basis, targeting individuals at increased risk of ovarian cancer. By identifying genetic markers associated with higher cancer risk, this initiative aims to empower participants with crucial information that can lead to proactive management and potentially life-saving preventive measures. This testing is part of a broader effort to enhance understanding and prevention of ovarian cancer, aligning with ongoing research and support to those impacted by the disease.
